Navigation Links
Biomarkers predict brain tumor's response to therapy
Date:6/23/2009

PHILADELPHIA A report in Cancer Research, a journal of the American Association for Cancer Research, highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain tumors, who would respond better to anti-vascular endothelial growth factor therapy, specifically cediranib.

Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. It is an investigational, oral agent that is administered once daily. Using a form of magnetic resonance imaging (MRI) that looked at the mechanism of action of this agent, the researchers were able to determine, even as early as after a single dose of cediranib, those patients who benefited from the agent and those who did not.

"We found that results from an advanced MRI scan taken just a day after starting treatment correlated with survival. Combining MRI with blood biomarkers did an even better job of identifying patients who best responded to treatment," said researcher A. Gregory Sorensen, M.D., associate professor of radiology and health sciences and technology at Harvard Medical School, Massachusetts General Hospital. "If this approach is validated in larger studies, we could use these tools to keep patients on therapies that their tumors respond to, and shift non-responders to other therapies much earlier."

Sorensen and colleagues sought to find the potential biomarkers that could be used to predict those patients who would respond better from antiangiogenic therapy early in the course of treatment by use of MRI.

The researchers measured vascular normalization prior to and one day after patients' received cediranib using an advanced MRI technique. They performed blood analysis and examined correlations between vascular parameters and treatment response after a single dose of cediranib in 31 patients with recurrent glioblastoma; all biomarkers were measured in 28 patients.

"Vascular normalization is an important mechanism of how these drugs work in cancer patients," said Rakesh K. Jain, Ph.D., Andrew Werk Cook professor of tumor biology at Harvard Medical School and director of the Edwin L. Steele Laboratory for Tumor Biology in the department of radiation oncology at Massachusetts General Hospital Cancer Center, Boston. Jain is also a researcher on this study.

The correlative analysis in this single arm, phase II study showed that those patients whose extent of vascular normalization was greater, had a longer duration of overall survival as well as progression-free survival, according to Jain. Median overall survival rate was 227 days; some patients lived for about two years and some lived less than two months.

"I was intrigued by the findings from this innovative trial, especially the fact that you could use separate biomarkers in combination to potentially predict the outcomes of patients," said Richard B. Gaynor, M.D., Ph.D., deputy editor of Cancer Research. Gaynor is the vice-president of cancer research at Eli Lilly and Company.

"This is really a severe disease and being able to determine response at such an early point is helpful to tailor treatment," he said. "If we can predict those responding to antiangiogenic therapy early on, we may be able to define where the benefit would be."

These findings need to be validated in larger, prospective studies. The researchers are currently conducting several studies based on these promising results in efforts to evaluate the benefits and prolonged survival of these patients.

One study is a phase III, randomized, multicenter, international trial that will compare patients treated with standard chemotherapy, those treated with cediranib, and those treated with a combination of the two to evaluate the effects and prolongation of life in all three cohorts. Approximately 300 patients are enrolled in this study, with enrollment halfway complete, according to Jain.

Another study, which just began enrollment, is a phase II, single-arm trial among patients who are newly diagnosed with glioblastoma. Researchers plan to evaluate treatment effects in patients treated with this agent combined with standard radiation and chemotherapy.

"We hope to develop biomarkers to help physicians and researchers know if a patient is responding; if they are not responding we can move them to a more effective therapy, if they are responding we can continue treatment, even if the treatment carries risks or side effects," Sorensen said.


'/>"/>

Contact: Tara Yates
tara.yates@aacr.org
267-646-0558
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Penn School of Medicine receives $2.3 million to study biomarkers of cigarette smoke exposure
2. Study makes progress in zoning in on biomarkers for better colon cancer treatment
3. Biomarkers predict risk for invasive breast cancer years before the tumor develops
4. JDRF and Lilly partner to fund research to identify beta cell biomarkers
5. Biomarkers for Alzheimers disease can be trusted in clinical trials
6. New developments in biomarkers for epithelial ovarian cancer
7. Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer
8. UCLA researchers discover biomarkers that predict lung cancer patient response to therapy
9. Biomarkers for Mood May Alter Psychiatric Treatments
10. Biomarkers and Innovation Push Global Cancer Diagnostics Market Toward $8 Billion
11. Scientists: New technique identifies molecular biomarkers for disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well has launched two ... drinks have been produced in collaboration with Zlatan Ibrahimovic and have been developed ... After a successful launch in Sweden last year, the next generation sports drinks ...
(Date:1/20/2017)... ... ... Angel”: a heartwarming and earnest tale of faith and believing in the path ... the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, alumnus of The ... of her new book, Marjorie says, “‘The Angel’ was written as a fairytale, but ...
(Date:1/20/2017)... ... 2017 , ... “I Forgive You”: a fine examination of how God handles sin, including ... of published author, Stephen Miller, who, for over ten long years has been waiting to ... in Trinidad and Tobago, he has been serving the Lord for over twenty years, and ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Christmas in ... creation of published author, Sara Seymour, who lives in Lafayette, Indiana where she works ... sips on iced coffees and writes. , Published by Christian Faith Publishing, Sara Seymour’s ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Knowledge is God’s Lighthouse”: a moving and ... God’s Lighthouse” is the creation of published author, Gene Gaapf, a retired truck driver, ... , “I have been writing since high school and have many different titles,” Gaapf ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... 2017 Research and Markets has announced ... Opportunities, and Future" report to their offering. ... This research service on the ... technologies, and provides a snapshot of the key participants in the ... are provided from 2016 to 2020. The market is expected to ...
(Date:1/20/2017)... -- Avillion LLP, a co-developer and financier of late-stage ... MD MBA as Chief Medical Officer. Dr Weinberg will be based ... ... spent more than 17 years as a pharmaceutical and biotech executive ... Over the course of his career, he has interfaced with the ...
(Date:1/19/2017)... , Jan. 19, 2017 The Global Therapy ... and access to partnering deals and agreements entered into ... in partnering deals - Top deals by value - ... development, technology type The report provides understanding and ... by the world,s leading healthcare companies. The report ...
Breaking Medicine Technology: